Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Leukemia
Lymphoma
Sarcoma

First Posted Date: 2004-05-25

Last Posted Date: 2011-03-28

Lead Sponsor: NYU Langone Health

Registration Number: NCT00004105

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Biological: recombinant interferon alfa
Drug: chemotherapy
Drug: paclitaxel
Drug: topotecan hydrochloride
Radiation: lutetium Lu 177 monoclonal antibody CC49
Radiation: yttrium Y 90 monoclonal antibody CC49

First Posted Date: 2004-05-24

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00002734

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-24

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 73

Registration Number: NCT00003004

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Estramustine phosphate sodium
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Paclitaxel
Drug: Ketoconazole
Drug: Vinblastine

First Posted Date: 2004-05-24

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT00003084

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Testicular Germ Cell Tumor

First Posted Date: 2004-05-24

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 44

Registration Number: NCT00003518

Locations: 🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States
🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
CCOP - Ochsner, New Orleans, Louisiana, United States

and more 16 locations

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-05-24

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003614

Locations: 🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 25 locations

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-05-21

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 384

Registration Number: NCT00003322

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 64 locations

Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: oxaliplatin
Drug: paclitaxel

First Posted Date: 2004-05-21

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 38

Registration Number: NCT00004126

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 8 locations

Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

Phase 2

Conditions: Esophageal Cancer

First Posted Date: 2004-05-20

Last Posted Date: 2008-07-24

Lead Sponsor: Theradex

Target Recruit Count: 100

Registration Number: NCT00003326

Locations: 🇺🇸
Akron City Hospital, Akron, Ohio, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Nevada Cancer Center, Las Vegas, Nevada, United States

and more 27 locations

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 3

Conditions: Breast Cancer

First Posted Date: 2004-05-20

Last Posted Date: 2013-12-18

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 1000

Registration Number: NCT00005581

Locations: 🇮🇹
Ospedale S. Paolo, Savona, Italy
🇮🇹
Ospedale Oncologico A. Businco, Cagliari, Italy
🇮🇹
I.R.C.C.S. Policlinico San Matteo, Pavia, Italy

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy